This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Tokyo University of Science Foundation, Kagawa University, Saga University. Active years: 2015-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2015-2016
Title: Fumio Fukai: Innovator in Anticancer Research
Introduction
Fumio Fukai is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of biomedical research, particularly in the development of innovative solutions for cancer treatment. With a total of 2 patents, his work focuses on enhancing the efficacy of anticancer agents and addressing chronic inflammation.
Latest Patents
Fukai's latest patents include an "Activity enhancer for anticancer agent" and a "Remedy for chronic inflammation and antibody to be used therein." The activity enhancer patent describes a D-form amino acid residue-containing FNIII14 polypeptide that serves as an active ingredient to improve the effectiveness of anticancer agents. The second patent provides a remedy for chronic inflammation, featuring an anti-TNIIIA2 antibody that recognizes a specific peptide derived from human tenascin-C fibronectin.
Career Highlights
Throughout his career, Fumio Fukai has been associated with prestigious institutions such as the Tokyo University of Science Foundation and Saga University. His work has been instrumental in advancing research in the medical field, particularly in developing new therapeutic strategies.
Collaborations
Fukai has collaborated with notable colleagues, including Takuya Matsunaga and Hiroaki Kodama. These partnerships have contributed to the success of his research endeavors and the development of his patented inventions.
Conclusion
Fumio Fukai's innovative work in anticancer research and chronic inflammation remedies highlights his significant impact on the biomedical field. His contributions continue to pave the way for advancements in cancer treatment and therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile